Expanding Accessibility to CD19-CAR T Cells: Commercializing a “Boutique” Therapy Premal Lulla, Carlos A. Ramos Molecular Therapy Volume 25, Issue 1, Pages 8-9 (January 2017) DOI: 10.1016/j.ymthe.2016.12.002 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions
Figure 1 Centralized CD19 CAR T Cell Manufacturing CD19 CAR T cell products are manufactured centrally from shipped patient apheresis units. Clinical grade products are then cryo-shipped back to the respective patients’ institutions for infusion. Molecular Therapy 2017 25, 8-9DOI: (10.1016/j.ymthe.2016.12.002) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions